Read Content Only
select font size Increase Font Size twelve pixels Increase Font Size fourteen pixels Increase Font Size sixteen pixels Email this link print page content
Principal Investigator(s): Charles B. Carpenter, MD
Mohamed H. Sayegh, MD (Director)
Anil Chandraker, MD
Group Member(s): Mark Denton, MD
Markus Frank, MD
Alan Salama, MB MRCP PhD
Nader Najafian, MD
Reza Abdi, MD
Shona Pendse, MD
Xueli Yuan, MD PhD
Isabelle Schmidt, MD
Ali Nayer, MD
Javeed Ansari, MB MRCP
Jean P. Kut, M.Ed.
Cheng Kwok, MS

Transplantation tolerance has remained the overarching goal of many investigators in the transplantation immunology. Our laboratory has pursued this goal through the use of animal models to test a variety of MHC derived peptides, monoclonal antibodies and fusion proteins aimed at T cell costimulatory pathways. While "tolerance-like" states are relatively easy to achieve in many models, robust tolerance is a different matter and our research involves characterizing the cellular and molecular pathways responsible for the development of this state. Another major area of interest is the mechanisms involved in the development of chronic allograft dysfunction (CAD), we have developed animal models to examine both alloantigen-dependent and -independent factors that contribute to CAD. In addition to the use of vascularized models of solid organ transplantation, mechanisms of rejection and tolerance in a cellular transplant setting, are also being studied in a model of pancreatic islet cell transplantation. The regulation of the immune response in human transplant recipients is also being examined, through collaborative studies utilizing steroid free immunosuppression at the Brigham and Women's Hospital for renal and islet cell transplant recipients. The laboratory is primarily funded by NIH research grants.

Recent Publications:

  1. Sayegh MH, Akalin E, Hancock WW, Russell ME, Carpenter CB, Linsley PS, Turka LA. Delayed blockade of CD28-B7 after alloantigenic challenge in vivo inhibits Th1 cytokines but spares Th2. J. Exp. Med. 1995;181:1869.

  2. Chandraker A, Azuma H, Nadeau K, Carpenter CB, Tilney NL, Hancock W, Sayegh M. Late blockade of T cell costimulation interrupts progression of experimental chronic allograft rejection. J. Clin. Invest. 1998;101:2309.

  3. Wekerle T, Kurts J, Ito H, Ronquillo JV, Dong V, Shao G, Shaffer J, Sayegh MH, Sykes M. allogeneic bone marrow transplantation with costimulatory blockade induces macroshimerism and tolernce without toreductive host treatment. Nature Medicine 2000; 6: 464-469

  4. Waaga AM, Gasser M, Kist-van Holthe JE, Najafian N, Muller A, Vella JP, Womer KL, Chandraker A, Sayegh MH. Regulatory functions of MHC class II allopeptide-specific Th2 clones in vivo. J. Clin. Invest. 2001; 107: 909-916.

  5. Dong VM, Yuan X, Coito AJ, Waaga AM, Sayegh MH, and Chandraker A. Mechanisms of Targeting CD28 by a Signaling Monoclonal Antibody in Acute and Chronic Allograft Rejection. Transplantation (in press).
Send Feedback   Send Feedback to: Michelle Deraney at mderaney@partners.org
This page was last modified on 2/10/2008